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Abstract: The aim of the present study was to look into the possible protective effects  
of glycyrrhizic acid (GA) against isoproterenol-induced acute myocardial infarction in 
Sprague-Dawley rats. The effect of three doses of glycyrrhizic acid in response to 
isoproterenol (ISO)-induced changes in 8-isoprostane, lipid hydroperoxides, super oxide 
dismutase and total glutathione were evaluated. Male Sprague-Dawley rats were divided 
into control, ISO-control, glycyrrhizic acid alone (in three doses-5, 10 and 20 mg/kg BW) 
and ISO with glycyrrhizic acid (in three doses) groups. ISO was administered at 85 mg/kg 
BW at two consecutive days and glycyrrhizic acid was administered intraperitoneally for 
14 days. There was a significant increase in 8-isoprostane (IP) and lipid hydroperoxide 
(LPO) level in ISO-control group. A significant decrease in total superoxide dismutase 
(SOD) and total glutathione (GSH) was seen with ISO-induced acute myocardial 
infarction. Treatment with GA significantly increased SOD and GSH levels and decreased 
myocardial LPO and IP levels. Histopathologically, severe myocardial necrosis and nuclear 
pyknosis and hypertrophy were seen in ISO-control group, which was significantly  
reduced with GA treatment. Gycyrrhizic acid treatment proved to be effective against  
isoproterenol-induced acute myocardial infarction in rats and GA acts as a powerful 
antioxidant and reduces the myocardial lipid hydroperoxide and 8-isoprostane level. 
OPEN ACCESS
Int. J. Mol. Sci. 2011, 12           
 
 
7101
Keywords: oxidative stress; isoproterenol; glycyrrhizic acid; lipid hydroperoxides;  
8-isoprostane 
 
1. Introduction 
Myocardial infarction (MI) occurs when there is myocardial necrosis due to prolonged imbalance 
between the myocardial oxygen supply and demand of the myocardium [1]. Myocardial infarction is 
said to be part of a spectrum of diseases known as Acute Coronary Syndromes (ACS). The diseases 
that make up the spectrum are unstable angina, acute myocardial infarction, and sudden cardiac  
death [2,3]. Among the various proposed mechanisms, the accumulations of free radicals have been 
implicated in the pathophysiology of acute myocardial infarction [4]. Isoproterenol is a  
beta-adrenoceptor agonist that induces myocardial infarction by causing imbalance between oxidants 
and antioxidants in the myocardium [5,6]. 
Several antioxidants have been tested for their possible protective actions against acute myocardial 
infarction [7,8]. Antioxidants suppress the formation of reactive oxygen species and shift the balance 
towards antioxidants from pro-oxidants, which accumulate to protect the myocytes [6,9]. Glycyrrhizic 
acid (GA) is a triterpenesaponin glycoside, which is the primary bioactive component of the main 
extract of the root of the plant GlyccyrhizaGlabra (Liquorice), a shrub from the Leguminosae  
family [10,11]. Research has shown that glycyrrhizic acid exhibits anti-ulcerative, expectorant,  
anti-viral, anti-inflammatory, anti-diabetic, anti-cancer, neuroprotective, and immune enhancing 
properties [10,12,13]. A recent report by Lee et al. [11] demonstrated that glycyrrhizic acid was also 
able to attenuate oxidative damage induced by carbon tetrachloride induced hepatic damage in mice. 
Another report [14] shows that glycyrrhizic acid is able to reduce oxidative stress damage in ischemia 
reperfusion injuries.  
In view of the protective role of antioxidants against isoproterenol-induced myocardial infarction, 
we have taken up the present research to evaluate the cardioprotective effect of glycyrrhizic acid 
against acute myocardial ischemia. Molecular mechanism of glycyrrhizic acid was studied through 
biochemical and histopathological approach in this study. We hypothesized that glycyrrhizic acid has a 
cardioprotective effect against isoproterenol-induced myocardial damage. 
2. Results and Discussion 
2.1. Body Weight and Heart Weight 
There was a significant difference in the body weight between control and ISO-control group  
(p < 0.05). Isoproterenol treatment significantly decreased the body weight of the rats, compared to 
control and GA alone groups (p < 0.05). Treatment with GA for ISO groups significantly increased  
(p < 0.05) the body weight and GA-20 mg dose was able to increase the body weight to near normal 
control level. ISO treatment significantly increased (p < 0.05) the heart weight showing ISO-induced 
cardiac hypertrophy in rats. GA treatment to ISO groups significantly reduced the heart weight  
(p < 0.05) than ISO-control group, but GA-5 mg group had higher heart weight than control rats. A 
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higher dose of GA significantly reduced (p < 0.05) cardiac hypertrophy caused by isoproterenol 
treatment (Table 1). 
Table 1. Effect of glycyrrhizic acid on body weight and heart weight in  
isoproterenol-induced rats. 
Groups Body Weight (g) Heart Weight (g) 
Control 202.43 ± 4.47 0.263 ± 0.021 
GA-5 196.12 ± 3.21 a 0.289 ± 0.029 
GA-10 205.34 ± 4.85 0.291 ± 0.020 a 
GA-20 210.09 ± 5.21 a 0.267 ± 0.031 
ISO-Control 183.56 ± 3.64 a 0.398 ± 0.031 a b 
ISO + GA-5  190.34 ± 4.21 a b 0.306 ± 0.008 a b 
ISO + GA-10  195.87 ± 3.20 c 0.287 ± 0.012 c 
ISO + GA-20  198.34 ± 2.22 c 0.280 ± 0.020 c 
Values are given as means ± S.D. for six rats. a Significantly different from control (p < 0.05);  
b Significantly different from GA alone treatment group (p < 0.05); c Significantly different from  
Iso-control group (p < 0.05). 
2.2. Cardiac Marker Enzymes 
There was a significant increase in mean CK-MB levels in the ISO alone group when compared to 
the control group (p < 0.05). When the control group was compared with ISO groups treated with all 
three doses of GA, a significant increase in mean CK-MB levels was also seen (p < 0.05). There was 
no significant difference between ISO groups treated with 5 mg GA, 10 mg GA, and 20 mg GA  
(p > 0.05). When compared between ISO alone group with ISO groups treated with all three doses of 
GA, a significant reduction of CK-MB levels was seen (p < 0.05). During pair-wise comparison, a 
significant increase of mean LDH levels was found in the SO-control group when compared to the 
control group (p < 0.05). ISO with 5, 10 and 20 mg GA, also showed a significantly higher level of 
LDH when compared to the control group (p < 0.05). There was no significant difference between 
LDH levels with GA alone treatment at different doses (Table 2). 
Table 2. Effect of glycyrrhizic acid on serum cardiac markers in isoproterenol-induced rats. 
Groups CK-MB (U/L) LDH (mmol/L) 
Control 3.763 ± 0.371 20.318 ± 1.407 
GA-5  3.601 ± 0.238 18.942 ± 0.751 
GA-10  3.669 ± 0.412 20.308 ± 1.581 
GA-20  3.593 ± 0.623 20.319 ± 0.845 
ISO-Control 10.702 ± 0.741a b 72.224 ± 2.641a b 
ISO + GA-5  7.562 ± 0.817 a b c 39.283 ± 2.794a b c 
ISO + GA-10  6.372 ± 0.552 a b c 34.789 ± 2.981 a b c 
ISO + GA-20  6.455 ± 0.848 a b c 37.617 ± 3.423 a b c 
Values are given as means ± S.D. for six rats. a Significantly different from control (p < 0.05);  
b Significantly different from GA alone treatment group (p < 0.05); c Significantly different from  
Iso-control group (p < 0.05). 
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2.3. Lipid Hydroperoxides 
When compared with the pair-wise technique, the ISO-control group showed a significant increase 
(p < 0.05) in cardiac LPO levels compared to the control group. GA alone treated groups at all three 
doses did not show any significant change in LPO level. GA treatment to ISO groups resulted in 
significant decrease (p < 0.05) in LPO level, compared to the ISO-control group. GA at all three doses 
decreased LPO levels significantly, but the level was significantly higher (p < 0.05) than control rats 
(Figure 1). 
Figure 1. Effect of glycyrrhizic acid on tissue lipid hydroperoxide (LPO) level  
(nmol/mg protein) in isoproterenol-induced rats. Values are given as means ± S.D. for  
six rats. a: Significantly different from control (p < 0.05); b: Significantly different from 
glycyrrhizic acid (GA) alone treatment group (p < 0.05); c: Significantly different from  
Iso-control group (p < 0.05). 
 
2.4. 8-Isoprostane 
Treatment with isoproterenol produced a significant increase in 8-Isoprostane (IP) as compared to 
the control group (p < 0.05). There was no significant difference seen between non-ISO groups treated 
with all three doses of GA, when compared to the control group (p > 0.05). Upon induction of MI with 
isoproterenol, the ISO-control group showed significantly higher IP levels as compared to the GA 
alone groups and control group (p < 0.05). When ISO groups were treated with all three doses of GA, 
levels of IP dropped to levels significantly lower than those of ISO-alone group (p < 0.05). In ISO + 5 mg 
GA, the level dropped, but only to a level that still showed difference which was significantly higher 
than the control group (p > 0.05). For ISO-10 mg GA and ISO-20 mg GA however, levels of IP 
dropped even further to the point that they were closer to that of control group (Figure 2). 
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Figure 2. Effect of glycyrrhizic acid on tissue 8-isoprostane level (pg/mL/mg protein) in 
isoproterenol-induced rats. Values are given as means ± S.D. for six rats. a: Significantly 
different from control (p < 0.05); b: Significantly different from GA alone treatment group 
(p < 0.05), c: Significantly different from Iso-control group (p < 0.05). 
 
2.5. Superoxide Dismutase 
Total SOD decreased significantly after isoproterenol treatment (p < 0.05), but treatment with GA 
significantly increased the SOD levels after 14 days (p < 0.05). ISO with GA-5, 10 and 20 mg/kg, 
increased the SOD levels more than ISO-control group (p < 0.05) and this level was significantly 
higher than the control group (p < 0.05). GA alone at 20 mg/kg at three doses significantly increased  
(p < 0.05) total SOD level, more than control group (Figure 3). 
Figure 3. Effect of glycyrrhizic acid on tissue total SOD level (U/mg protein) in 
isoproterenol-induced rats. Values are given as means ± S.D. for six rats. a: Significantly 
different from control (p < 0.05); b: Significantly different from GA alone treatment group 
(p < 0.05); c: Significantly different from Iso-control group (p < 0.05). 
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2.6. Total Glutathione 
The isoproterenol alone group showed a significant fall in the mean level of GSH when compared 
to the control group (p < 0.05). Following administration of 20 mg/kg body weight GA to  
non-ISO groups, mean levels of GSH increased significantly when compared to control group and ISO 
alone group (p < 0.05). In contrast, the ISO-control group showed a significant decrease in mean GSH 
levels when compared to control group (p < 0.05). This was reversed upon treatment with all three 
doses of GA, causing levels of GSH to rise to be significantly higher than the MI alone group  
(p < 0.05). ISO + 5 mg GA rose to a level more or less similar to that of the control group with 
statistical test showing no significant difference between them (p > 0.05). ISO + 10 mg GA and  
ISO + 20 mg GA showed significantly higher GSH than those of the control group (p < 0.05) (Figure 4).  
Figure 4. Effect of glycyrrhizic acid on tissue total glutathione (GSH) level (nmol/mg 
protein) in isoproterenol-induced rats. Values are given as means ± S.D. for six rats.  
a: Significantly different from control (p < 0.05); b: Significantly different from GA alone 
treatment group (p < 0.05); c: Significantly different from Iso-control group (p < 0.05). 
 
2.7. Histopathological Analyses 
The myocardium showed adequate cellularity and normal morphology. Myocytes were healthy and 
there was no evidence of myocyte necrosis, nuclear pyknosis, vascular proliferation, macrophage 
activity, scar formation, or muscle hypertrophy. Treatment with glycyrrhizic acid alone at three doses 
showed that the myocardium was similar to that of the control group with adequate cellularity and 
normal morphology. No evidence of necrosis, nuclear pyknosis, angiogenesis, vascular proliferation, 
macrophage activity, scar formation, or muscle hypertrophy was seen (Table 3, Figure 5). In the  
ISO-control group there were morphological changes that were strongly suggestive of  
isoproterenol-induced myocardial injury were seen. Large areas of coagulative necrosis were seen with 
neutrophilic infiltrate, diffused interstitial edema and pale myocytes with fading nuclei and decreased 
striations. Nuclear pyknosis and clumping of cytoplasm was evident throughout areas of necrosis. In 
ISO groups treated with GA, many areas of myocyte debris were disintegrated with the presence of 
macrophages, suggesting that the myocytes were removed by macrophage activity. Macrophage 
activity was prominent in areas of injury and it increased in order of the increasing doses of GA. This 
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was also true for areas of scar formation, and areas of vascular proliferation which were both present in 
numerous areas throughout the myocardium and increased in order of the increasing doses of GA. 
Increased areas of scar formation, vascular proliferation and macrophage activity were indicative of 
better healing following myocardial infarction (Table 3, Figure 5). 
Table 3. Effect of glycyrrhizic acid on histopathological changes in the hearts of  
isoproterenol-induced rats. 
Groups Necrosis Pyknosis Angiogenesis Scar 
Formation
Hypertrophy Macrophage 
Activity 
Control − − − − − − 
GA-5  − − − − − − 
GA-10  − − − − − − 
GA-20  − − − − − − 
ISO-Control +++ ++ ++ + ++ ++ 
ISO + GA-5  ++ ++ ++ + + + 
ISO + GA-10  + + ++ + + + 
ISO + GA-20  + + +++ ++ + + 
Histopathological changes; −No change, + Mild, ++ Moderate, +++ Severe. 
Figure 5. Histopathological analysis of rat myocardium: (A) Normal appearance 
myocardial tissue in control rats. (B) Normal myocardium without any necrosis or nuclear 
pyknosis in GA alone group. (C) Myocardial infarction with ISO treatment showing 
necrosis and scar formation. (D) Vascular proliferation and macrophage activity in  
ISO + GA treated group (200×). 
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3. Discussion 
The results of the present study showed that there was significant increase in oxidative stress after 
myocardial ischemia in rats and glycyrrhizic acid showed a significant protective effect against this 
oxidative damage. There was no significant difference in the effect of different dose of glycyrrhizic 
acid in majority of the parameters studied. 
There was a significant elevation in serum lactate dehydrogenase (LDH) and creatine kinase-MB 
(CK-MB) confirming the acute myocardial infarction in rats. These observations are in line with 
previous studies done on rats treated with isoproterenol [15,16]. The myocardial cells contain many 
cardiac enzymes like creatinine kinase, lactate dehydrogenase, asparate transaminase etc. Upon 
administration of isoproterenol, the oxygen demand of the heart increases with increase in ionotropic 
effect in the heart, resulting in prolonged ischemia and glucose deprivation. The cells are damaged 
with increased muscle contractility, which results in increasing the cell membranes permeability 
allowing cardiac enzymes to leak out into the bloodstream [9,15–18]. Creatine kinaseis an enzyme 
capable of reversibly transferring a phosphate group from the energy storage form of creatine 
phosphate, to a molecule of ADP, producing ATP [19]. CK-MB is localized predominantly in the heart 
and this makes it a valuable diagnostic tool for MI since damage specific to the myocardium would 
result in elevation of CK-MB levels [19–21]. CK- MB estimation is considered the standard to which 
all cardiac biomarkers will be compared to [19,22]. LDH has been used traditionally as a nonspecific 
diagnostic tool for myocardial infarction. A rise in the proportion of LDH in the serum can be 
diagnostic of myocardial infarction [23,24]. LDH usually rises within 6–12 hours of MI. Level of LDH 
peaks within 48 hours, remains at that peak for 4–14 days. Histopathological study also confirmed the 
myocardial damage with ISO treatment. There were nuclear pyknosis and necrosis in the myocardium. 
Vascular proliferation, interstitial edema, increased macrophage activity, scar formation, and 
myocardial hypertrophy confirmed the myocardial infarction with isoproterenol treatment [15,16,25]. 
An increase in oxidative stress was recorded during and following myocardial infarction by many 
researchers [26–29]. This may cause oxidative damage to proteins and lipids interfering with myocyte 
structure and functions. The observed increasein LPO with isoproterenol could be because of 
formation of free radicals and also through exhaustion of antioxidants, leading to oxidative stress. 
Stimulation of beta adrenergic receptors with isoproterenol treatment generates excess reactive oxygen 
species in myocardium [9,16]. Reactive oxygen species (ROS) attack polyunsaturated fatty acids, 
which is the precursor of lipid peroxide formation [30]. Increased myocardial LPO is suggestive of 
lipid accumulation and irreversible myocardial damage. Intense lipid peroxidation caused by isoproterenol 
may affect the mitochondrial and cytoplasmic membrane causing more severe oxidative damage in the 
heart and consequently releasing LPO into circulation [30–32]. 
Although isoprostanes can be produced by cyclooxygenase enzymes in vitro and in vivo, its 
production in vivo is almost entirely attributed to oxidation of lipids due to reactive oxygen  
species [33]. In fact, the majority of IPformation happens in the esterified arachidonic acids in 
membrane phospholipids. These IP are then released into the circulation by the action of 
phospholipases [34]. Aside from just being markers of lipid peroxidation, isoprostanes have also been 
shown to possess biological activity and are capable of mediating oxidative stress. Increased  
8-isoprostane in this study with ISO confirms the oxidative stress in myocardium. Isoprostane has 
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vasoconstriction and platelet aggregation property which might have aggravated the myocardial injury 
with ISO treatment [35,36]. 
Increase in oxidative stress with ISO treatment causes oxidation of lipids, proteins and DNA in the 
myocardium causing alteration in cell structure and function. This eventually leads to myocardial 
injury. The ISO alone group showed a significant decrease in myocardial endogenous antioxidants 
SOD and GSH when compared to control and non-MI groups. Isoproterenol is a synthetic 
catecholamine and catecholamines rapidly undergo oxidation and oxidation products of metabolism 
will have significant effect on myocardium. SOD, and GSH take part in maintaining glutathione 
homeostasis in the tissues. These antioxidants are involved in the defense system against free radical 
mediated tissue or cellular damage [15,16,18,21]. 
GSH is ubiquitous antioxidant, and essential biofactor synthesized in all living cells. It protects the 
cells from free radical mediated injury caused by drugs. It forms an important substrate for several 
other antioxidant enzymes. SOD activity decreased significantly with isoproterenol due to an excessive 
formation of superoxide anions. A decrease in SOD activity may result in the decreased removal of 
superoxide anions, which can cause free radical-induced myocardial damage [37,38]. Decrease in the 
level of SOD and GSH in myocardium is in close relationship with increased LPO and 8-IP. SOD  
and GSH are the primary defense antioxidants, the level of which depleted significantly with  
isoproterenol-induced myocardial ischemia suggestive of severe oxidative stress in the heart.  
Treatment with glycyrrhizic acid decreased LPO and IP levels and increased SOD and GSH level in 
the heart. This supports the scavenging activities of GA and protecting the myocardial antioxiodant 
enzymes. A recent study [11] showed that GA was capable of reducing oxidative stress and lipid 
peroxidation caused by carbon tetrachloride induced liver injury in mice [11,14]. Other studies have 
been recorded that also state the antioxidant properties of GA [14,39]. GA’s antioxidant properties 
could be due to the fact that it is able to achieve maximum conjugation with free radicals, thus 
neutralizing them [11]. GA is also capable of reducing the production of free radicals by neutrophils 
and interfering with neutrophil chemotaxis [10,14]. Considering neutrophils play a major role in the 
pathogenesis of acute myocardial infarction, inhibition of their ROS formation will significantly 
reduce oxidative stress during myocardial infarction. GA’s ability to neutralize free radicals and to 
interfere with neutrophil chemotaxis and ROS formation makes it a useful antioxidant for reducing 
oxidative stress during infarction. This confirms that GA is a good cardioprotective agent. Apart from 
this, GA administration in non-ISO groups caused an increase in endogenous antioxidants SOD and 
GSH as well which suggest that GA may be able to independently increase the pool of GSH and SOD 
in the myocardium without the presence of oxidative stress and neutrophils. This confirms that the 
antioxidant effects of GA increase endogenous antioxidant enzymes even in normal cardiac tissue. 
Relatively very few data are available about the antioxidant properties of glycyrrhizic acid. In fact, this 
is the first study reporting the antioxidant and cardioprotective effects of glycyrrhizic acid in 
isoproterenol-induced myocardial ischemia in rats. When the effects of three different doses of GA 
were compared, it was observed that the higher dose of GA (10 and 20 mg/kg body weight) had a 
significant effect than the lower dose (5 mg/kg body weight). 
Histopathological findings of isoproterenol treated rats showed infarction zone with myocardial 
necrosis, nuclear pyknosis, and hypertrophy and scar formation. Glycyrrhizic acid treatment to ISO 
groups had shown a significant protection against myocardial injury. Different dose of GA has shown 
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that many areas of myocyte debris were disintegrated with accumulation of macrophages, suggesting 
that the myocytes were removed by these macrophages. Myocardial healing was seen with different 
dose of GA in ISO treated rats suggesting protective function of GA in myocardial infarction. 
Treatment with GA alone at three doses did not show any necrosis or scar formation or hypertrophy. 
This indicates that glycyrrhizic acid does not possess any adverse effects to myocardium under  
normal conditions. 
4. Experimental Section 
Adult, male Sprague-Dawley rats (200–225 g) were used for this study. Rats were allowed to adapt 
to the laboratory conditions at least one week before the start of the experiments. The rats were placed 
in standard laboratory conditions on arrival in an air-conditioned room (25 ± 2 °C) with controlled  
12 h light/12 h dark cycles. Rats were placed in polypropylene cages (3 per cage). Food and water 
were available freely all the time except during the experimental procedures. All the experimental 
procedures were carried out according to the Guidelines for Ethical care and Use of Experimental 
Animals and the study protocol was approved by Institutional Research and Ethics Committee. 
Isoproterenol hydrochloride and glycyrrhizic acid were purchased from Sigma-Aldrich. The rats 
were randomly assigned into eight groups (six rats per group). Group 1, control; group 2, 3 and 4 
glycyrrhizic acid (GA) alone in three different doses (5, 10 and 20 mg/kg BW); group 5, ISO-control 
group; group 6, 7 and 8, ISO with GA (5, 10 and 20 mg/kg BW). Isoproterenol was administered 
subcutaneously (85 mg/kg BW) for two days. GA was administered intraperitoneally after 48 hours to 
all the rats in GA alone and ISO + GLY groups at three doses (5 mg/kg, 10 mg/kg and 20 mg/kg BW) 
for 14 days. 
Twenty-four hours after the last treatment, the rats were weighed, and then sacrificed with over 
dose of anesthesia (50 mg/kg BW of sodium pentobarbitol) and blood samples were collected by 
cardiac puncture. The heart was dissected and weighed. Blood was centrifuged and serum was 
separated from which cardiac biomarkers, creatinine kinase-MB (CK-MB) and lactate dehydrogenase 
were estimated spectrophotometrically using commercially available kits (Bioassay Systems, CA, 
USA). Part of the heart was dissected and homogenized immediately and supernatant was kept at  
−80 °C until further biochemical assay. From the homogenate samples, lipid hydroperoxides (LPO),  
8-isoprostane level (IP), total superoxide dismutase (SOD), total glutathione (GSH) and total protein 
levels were assayed using ELISA kits (Cayman Chemicals and Pierce Biotechnology, USA). Tissue 
LPO, IP, SOD and GSH levels were expressed per milligrams of proteins. Another portion of the heart 
was placed in formalin (10%). Paraffin blocks were prepared from the heart and thin sections were cut 
(4 µM) and stained with haematoxylin-eosin (H&E) using the staining protocol for light microscopic 
examination. The sections were evaluated under light microscope (200×) for necrosis, nuclear pyknosis, 
hypertrophy, angiogenesis, scar formation and macrophage activity. Severity of changes were graded 
using a scale of no change (−), mild changes (+), moderate changes (++) and severe changes (+++).  
4.1. Lipid Hydroperoxide (LPO) Assay 
A quantitative extraction method as provided in the ELISA kit method for LPO assay was used to 
extract lipid hydroperoxides into chloroform and the extract was directly used. This procedure 
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eliminates any interference caused by hydrogen peroxide or endogenous ferric ions in the sample and 
provides a sensitive and reliable assay for lipid peroxidation. The absorbance was read at 500 nm using 
96 well plate reader and a dose response curve of the absorbance unit versus concentration in nano 
moles was prepared. LPO levels were expressed as nmol/mg of protein.  
4.2. 8-Isoprostane (IP) Assay 
8-isoprostane assay is based on competition between 8-Iso and an 8-Iso-Acetylcholinesterase 
conjugate (tracer) for a limited number of rabbit antiserum sites. During the assay, the concentration of 
tracer was held constant while the concentration of 8-Iso varied according to sample. Therefore, 
amount of tracer able to bind with serum was inversely proportional to the concentration of 8-Iso. This 
rabbit antiserum complex then bound to the rabbit IgG antibodies previously attached to the wells. 
Plates are then washed to remove unbound reagents and Ellman’s reagent (contains tracer substrate) 
was added. The yellow mixture produced was quantified spectrophotometrically at absorbance of  
412 nm. IP were expressed as pg/mL/mg of protein. 
4.3. Superoxide Dismutase (SOD) Assay 
This assay kit utilizes a tetrazolium salt for the detection of total superoxide radicals (O2−) 
generated by xanthine oxidase and hypoxanthine. One unit of SOD is defined as the amount of enzyme 
necessary to exhibit 50% dismutation of superoxide radical. Oxidation rate of tetrazolium salt to 
formazan dye by O2− is inversely proportional to the endogenous activity of SOD. The formazan dye 
stains the 96 wells and its staining intensity was detected by absorbance spectrophotometry at 450 nm 
using a plate reader. Total SOD levels were determined from a standard curve and expressed as U/mg 
of protein. 
4.4. Total Glutathione (GSH) Assay 
Glutathione assay kit utilizes an optimized enzymatic recycling method that uses glutathione 
reductase for quantification of GSH. GSH exerts its antioxidant action through its sulfhydryl groups. 
This assay takes advantage of the sulhydryl groups reaction with DTNB (5,5'-dithio-bis-2-nitrobenzoic 
acid) producing a yellow coloured 5-thio-2-nitrobenzoic acid (TNB). The mixed disulfide of TNB and 
GSH produced is further reduced by glutathione reductase to recycle the GSH and produce more GSH. 
Rate of TNB production is directly proportional to the recycling reaction and the concentration of GSH 
in the tissue sample. TNB was then quantified spectrophotometrically at an absorbance of 405 nm. 
GSH was expressed as nmol/mg protein. 
4.5. Statistical Analysis 
All the results were reported as means with standard deviation. Graph Pad prism 5.0 software used 
for statistical analyses. Comparison between different groups were done using Kruskal Wallis one way 
analysis of variance test. Pair wise comparison between the different groups was done using  
Mann-Whitney-U test. p < 0.05 was considered to show statistical significance. 
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5. Conclusions 
Histopathological and biochemical findings of the present study indicate that glycyrrhizic acid 
possess antioxidant properties in myocardium and protects against isoproterenol-induced oxidative 
stress. The most important protective mechanism offered by glycyrrhizic acid is through its ability to 
decrease lipid hydroperoxides and isoprostanes and to increase the superoxide dismutase and 
glutathione level. Thus, glycyrrhizic acid has been shown to possess cardioprotective effect against 
isoproterenol-induced acute myocardial infarction in rats. 
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